HTLV-1 associated myelopathy/tropical spastic paraparesis
Alternate names[edit | edit source]
HAM/TSP; Human T-cell leukemia virus type 1 associated myelopathy/tropical spastic paraparesis; Tropical spastic paraparesis (formerly)
Definition[edit | edit source]
HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a progressive disease of the nervous system that affects less than 2% of people with HTLV-1 infection.
Cause[edit | edit source]
- The cause of TSP was obscure until the mid-1980s, when an important association was established between the human retrovirus — human T-cell lymphotrophic virus type 1 (also known as HTLV-1) — and TSP.
- TSP is now called HTLV-1 associated myelopathy/ tropical spastic paraparesis or HAM/TSP.
- The HTLV-1 retrovirus is thought to cause at least 80 percent of the cases of HAM/TSP by impairing the immune system.
Signs and symptoms[edit | edit source]
Signs and symptoms of HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) vary but may include:
- Slowly progressive weakness and spasticity of one or both legs
- Exaggerated reflexes (hyperreflexia)
- Stiff muscles
- Muscle contractions in the ankle (ankle clonus)
- Lower back pain
- A 'weak' bladder and/or urinary incontinence
- Minor sensory changes, especially burning or prickling sensations and loss of vibration sense
Diagnosis[edit | edit source]
Tropical spastic paraparesis can be diagnosed by using MRI (magnetic resonance imaging) and lumbar puncture (which may show lymphocytosis).
Treatment[edit | edit source]
- Treatment generally aims to control the specific symptoms, as there is no standard treatment available.
- Interferon alpha may be beneficial over short periods, and some aspects of the disease may be improved with interferon beta.
- Stiff and spastic muscles may be treated with lioresal or tizanidine, and urinary dysfunction may be treated with oxybutynin.
- Corticosteroids were reported to slow progression in one case series and reduce neurologic disability in another.
- However, others have reported no such benefit with corticosteroids and there have been no randomized clinical trials.
NIH genetic and rare disease info[edit source]
HTLV-1 associated myelopathy/tropical spastic paraparesis is a rare disease.
HTLV-1 associated myelopathy/tropical spastic paraparesis Resources | |
---|---|
|
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Deepika vegiraju